GENinCode (LON:GENI) Hits New 52-Week Low – Should You Sell?

GENinCode Plc (LON:GENI)’s share price hit a new 52-week low on Wednesday . The company traded as low as GBX 0.80 and last traded at GBX 0.95, with a volume of 14639052 shares changing hands. The stock had previously closed at GBX 0.88.

GENinCode Stock Up 8.1%

The stock has a fifty day moving average of GBX 1.11 and a two-hundred day moving average of GBX 1.49. The company has a quick ratio of 15.89, a current ratio of 0.93 and a debt-to-equity ratio of 117.74. The stock has a market cap of £6.86 million, a price-to-earnings ratio of -0.40 and a beta of 0.59.

GENinCode (LON:GENI) last announced its quarterly earnings results on Monday, June 8th. The company reported GBX (2.08) EPS for the quarter. The firm had revenue of GBX 308 million for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%. As a group, analysts predict that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.